Animal health company Elanco Animal Health Incorporated (NYSE: ELAN) said on Wednesday that it has agreed to sell the European Economic Area and UK rights to the Drontal and Profender product families from Bayer AG's (ETR:BAYN) animal health business.
French pharmaceutical company Vetoquinol SA (EURONEXT:VETO) will pay USD140m for the rights in an all-cash deal subject to customary post-closing adjustments.
Drontal and Profender are both de-wormers for dogs and cats.
Elanco stated that the sale of the rights to Drontal and Profender in the European Economic Area and the UK further advances its efforts to gain European Commission clearance for the acquisition of Bayer AG's global animal health business.
Closing of the transaction with Vetoquinol is contingent on Elanco closing its transaction with Bayer, as well as other customary closing conditions.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval